why choose us

300×250 Ad Slot

Research Article: Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for Helicobacter pylori infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Date Published: 2023-07-21

Abstract:
Introduction Helicobacter pylori is the most well-known risk factor for gastric cancer. Antibiotic resistance is the main reason for the failure of H. pylori eradication, and understanding the antibiotic resistance before treatment may be the main determinant of successful eradication of H. pylori . This study aims to evaluate the efficacy and safety of quadruple therapy based on faecal molecular antimicrobial susceptibility tests for the first-line eradication of H. pylori infection. Methods and analysis This is a single-centre, single-blind, randomised controlled trial, enrolling 855 patients with H. pylori infection. Patients are randomised to three groups for a 14-day treatment: group A: amoxicillin- and clarithromycin-based bismuth-containing quadruple therapy (BQT) (rabeprazole 10?mg, amoxicillin 1?g, clarithromycin 500?mg and colloidal bismuth 200?mg two times per day); group B: clarithromycin medication history-based BQT (rabeprazole 10?mg, amoxicillin 1?g, furazolidone 100?mg (with clarithromycin medication history)/clarithromycin 500?mg (without clarithromycin medication history) and colloidal bismuth 200?mg two times per day); group C: antimicrobial susceptibility test-based BQT (rabeprazole 10?mg, amoxicillin 1?g, clarithromycin 500?mg (clarithromycin-sensitive)/furazolidone 100?mg (clarithromycin resistant) and colloidal bismuth 200?mg two times per day). The primary end point is the eradication rate. The secondary end points are the incidence of adverse events and compliance. Ethics and dissemination This study was approved by the Ethics Committee of Second Affiliated Hospital, School of Medicine, Zhejiang University (Number 20230103). The results will be published in the appropriate peer-reviewed journal. Trial registration number NCT05718609 .

Introduction:
Helicobacter pylori was listed as a Class I carcinogen by the World Health Organization in 1994 and is closely associated with a variety of digestive tract diseases, such as chronic gastritis, peptic ulcer, gastric cancer and mucosa-assisted lymphoid tissue (MALT) lymphoma. 1 About 90% of non-cardia gastric cancer is associated with H. pylori infection and the eradication of H. pylori makes intestinal gastric cancer a preventable disease. 2 3 Amoxicillin-clarithromycin-containing bismuth-containing quadruple…

Read more

300×250 Ad Slot